ArticleMedicina oral, patologia oral y cirugia bucal2025
Antimicrobial activity of piperacillin/tazobactam against key peri-implant pathogens: an in vitro comparative study with amoxicillin-clavulanate and minocycline.
Article in Medicina oral, patologia oral y cirugia bucal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeri-implantitis is an inflammatory disease linked to bacterial biofilms that threatens the long-term success of dental implants. The growing problem of antibiotic resistance among peri-implant pathogens highlights the need to explore alternative antimicrobial agents with proven in vitro efficacy. MATERIAL AND
methodsThis in vitro study evaluated the antimicrobial activity of piperacillin/tazobactam compared with two commonly used antibiotics in dentistry: amoxicillin-clavulanate and minocycline. The minimum inhibitory concentrations (MICs) were determined using Etest® gradient diffusion strips against three key peri-implant pathogens: Porphyromonas gingivalis, Prevotella intermedia, and Aggregatibacter actinomycetemcomitans. Cultures were incubated under anaerobic conditions to simulate the peri-implant environment.
resultsPiperacillin/tazobactam demonstrated MIC values comparable to those of amoxicillin-clavulanate and minocycline for P. gingivalis and A. actinomycetemcomitans, and lower MICs against P. intermedia. Statistical analysis confirmed that piperacillin/tazobactam is not inferior to these widely used antibiotics.
conclusionsPiperacillin/tazobactam shows promising in vitro antimicrobial activity against key peri-implant pathogens and may serve as an effective alternative or adjunctive treatment in managing peri-implantitis. Further clinical studies are warranted to confirm its efficacy and safety in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.